排序方式: 共有47条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Tikki Pang 《Tropical medicine & international health : TM & IH》2009,14(4):379-380
5.
Thiem VD Danovaro-Holliday MC Canh do G Son ND Hoa NT Thuy DT Ochiai RL Lan NT Hop TQ Ali M Park JK Abu-Elyazeed R Holliday K Ivanoff B Anh DD Pang T Donner A Galindo CM Trach DD Clemens JD Acosta CJ 《The Southeast Asian journal of tropical medicine and public health》2006,37(3):515-522
We report the coverage, safety, and logistics of a school-based typhoid fever immunization campaign that took place in Hue City, central Vietnam; a typhoid fever endemic area. A cluster-randomized evaluation-blinded controlled trial was designed where 68 schools (cluster) were randomly allocated the single dose Vi polysaccharide vaccine (Typherix) or the active control hepatitis A vaccine (Havrix). A safety surveillance system was implemented. A total of 32,267 children were immunized with a coverage of 57.5%. Strong predictors for vaccination were attending primary schools, peri-urban location of the school, and low family income. Human resources were mainly schoolteachers and the campaign was completed in about 1 month. Most adverse events reported were mild. Safe injection and safe sharp-waste disposal practices were followed. A typhoid fever school-based immunization campaign was safe and logistically possible. Coverage was moderate and can be interpreted as the minimum that could have been achievable because individual written informed consent procedures were sought for the first time in Hue City and the trial nature of the campaign. The lessons learned, together with cost-effectiveness results to be obtained by the end of follow-up period, will hopefully accelerate the introduction of Vi typhoid fever vaccine in Vietnam. 相似文献
6.
7.
8.
Acosta CJ Galindo CM Ochiai RL Danovaro-Holliday MC Laure-Page A Thiem VD Jin Y Khan MI Sahito SM Hamza HB Park JK Lee H Bock H Elyazeed RA Albert MJ Ascaso C Robles TQ Ali M Ngai P Puri MK Koo YM Agtini MD Soeharno R Bai-qing D Kohl D Xu ZY Ivanoff B Jodar L Pang T Bhutta Z Clemens JD 《Vaccine》2007,25(15):2852-2857
The practicalities when applying the ICH GCPs (International Conference on Harmonization 1996 Good Clinical Practices [EU, MHLW, FDA. International Conference on Harmonization Guideline for Good Clinical Practice; 1997] in less developed countries (ldcs) are seldom discussed and we found no guidelines as how to "adapt" them. Below we illustrate how ICH GCP principles can be implemented in different settings. We have recently conducted in Asia (Hechi, China; Karachi, Pakistan; Hue, Vietnam; North Jakarta, Indonesia and Kolkata, India) large-scale cluster-randomized effectiveness evaluations of the Vi polysaccharide typhoid fever vaccine (Vi PS project) among approximately 200,000 individuals(1)[Acosta CJ, Galindo CM, Ali M, Abu-Elyazeed R, Ochiai RL Danovaro-Holliday MC et al. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. TMIH 2005;10(12):1219-1228]. There is no doubt on the importance of ICH GCP in its contribution to ethical and scientifically sound clinical research. However, when the ICH GCP is implemented in ldcs some considerations must be made in order to adequately tailor them. Vaccine trials in ldcs are a frequent setting for such challenges because of the increased global interest conducting health research in such countries. The ICH GCP principles are discussed below within the framework of this recent typhoid fever vaccine study experience. 相似文献
9.
10.
Hamid M Bustamante-Manaog T Truong VD Akkhavong K Fu H Ma Y Zhong X Salmela R Panisset U Pang T 《Lancet》2005,366(9499):1758-1760